Anbio Biotechnology to Participate in KeyBanc Capital Markets Healthcare ForumFRANKFURT AM MAIN, Germany, March 17, 2026 (GLOBE NEWSWIRE) -- Anbio Biotechnology (
NASDAQ: NNNN) ("Anbio" or the "Company"), a global diagnostic company in in-vitro diagnostic (IVD) technologies, announced today that its CEO will participate in the upcoming KeyBanc Capital Markets Virtual Healthcare Forum on Wednesday, March 18, 2026.
Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR SystemCovering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide.
Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May ExhibitionsAccelerating Expansion Across Human and Veterinary Health Through Innovation and Strategic Collaboration
